Report cover image

Global Proliferative Vitreoretinopathy (PVR) Therapeutics Industry Growth and Trends Forecast to 2031

Publisher APO Research, Inc.
Published Oct 20, 2025
Length 70 Pages
SKU # APRC20548692

Description

Summary

According to APO Research, The global Proliferative Vitreoretinopathy (PVR) Therapeutics market was estimated at US$ million in 2025 and is projected to reach a revised size of US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2026-2031.

North American market for Proliferative Vitreoretinopathy (PVR) Therapeutics is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.

Asia-Pacific market for Proliferative Vitreoretinopathy (PVR) Therapeutics is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.

Europe market for Proliferative Vitreoretinopathy (PVR) Therapeutics is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.

The major global manufacturers of Proliferative Vitreoretinopathy (PVR) Therapeutics include Novartis AG, RXi Pharmaceuticals Corp and Promedior Inc, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Proliferative Vitreoretinopathy (PVR) Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Proliferative Vitreoretinopathy (PVR) Therapeutics.
The Proliferative Vitreoretinopathy (PVR) Therapeutics market size, estimations, and forecasts are provided in terms of sales volume (k units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Proliferative Vitreoretinopathy (PVR) Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

Key Companies & Market Share Insights

In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.

Proliferative Vitreoretinopathy (PVR) Therapeutics Segment by Company

Novartis AG
RXi Pharmaceuticals Corp
Promedior Inc
Proliferative Vitreoretinopathy (PVR) Therapeutics Segment by Type

PRM-167
XOMA-089
Others
Proliferative Vitreoretinopathy (PVR) Therapeutics Segment by Application

Clinic
Hospital
ASCs
Others
Proliferative Vitreoretinopathy (PVR) Therapeutics Segment by Region

North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Proliferative Vitreoretinopathy (PVR) Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Proliferative Vitreoretinopathy (PVR) Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Proliferative Vitreoretinopathy (PVR) Therapeutics.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Proliferative Vitreoretinopathy (PVR) Therapeutics manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Sales, revenue of Proliferative Vitreoretinopathy (PVR) Therapeutics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.
Chapter 13: Concluding Insights of the report.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

70 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Market Growth Prospects
1.2.1 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Market Size Estimates and Forecasts (2020-2031)
1.2.2 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Estimates and Forecasts (2020-2031)
1.3 Proliferative Vitreoretinopathy (PVR) Therapeutics Market by Type
1.3.1 PRM-167
1.3.2 XOMA-089
1.3.3 Others
1.4 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Market Size by Type
1.4.1 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Market Size Overview by Type (2020-2031)
1.4.2 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Historic Market Size Review by Type (2020-2025)
1.4.3 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Forecasted Market Size by Type (2026-2031)
1.5 Key Regions Market Size by Type
1.5.1 North America Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Breakdown by Type (2020-2025)
1.5.2 Europe Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Breakdown by Type (2020-2025)
1.5.3 Asia-Pacific Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Breakdown by Type (2020-2025)
1.5.4 South America Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Breakdown by Type (2020-2025)
1.5.5 Middle East and Africa Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Breakdown by Type (2020-2025)
2 Global Market Dynamics
2.1 Proliferative Vitreoretinopathy (PVR) Therapeutics Industry Trends
2.2 Proliferative Vitreoretinopathy (PVR) Therapeutics Industry Drivers
2.3 Proliferative Vitreoretinopathy (PVR) Therapeutics Industry Opportunities and Challenges
2.4 Proliferative Vitreoretinopathy (PVR) Therapeutics Industry Restraints
3 Market Competitive Landscape by Company
3.1 Global Top Players by Proliferative Vitreoretinopathy (PVR) Therapeutics Revenue (2020-2025)
3.2 Global Top Players by Proliferative Vitreoretinopathy (PVR) Therapeutics Sales (2020-2025)
3.3 Global Top Players by Proliferative Vitreoretinopathy (PVR) Therapeutics Price (2020-2025)
3.4 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Industry Company Ranking, 2023 VS 2024 VS 2025
3.5 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Major Company Production Sites & Headquarters
3.6 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Company, Product Type & Application
3.7 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Company Establishment Date
3.8 Market Competitive Analysis
3.8.1 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Market CR5 and HHI
3.8.2 Global Top 5 and 10 Proliferative Vitreoretinopathy (PVR) Therapeutics Players Market Share by Revenue in 2024
3.8.3 2023 Proliferative Vitreoretinopathy (PVR) Therapeutics Tier 1, Tier 2, and Tier 3
4 Proliferative Vitreoretinopathy (PVR) Therapeutics Regional Status and Outlook
4.1 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Market Size and CAGR by Region: 2020 VS 2024 VS 2031
4.2 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Historic Market Size by Region
4.2.1 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales in Volume by Region (2020-2025)
4.2.2 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales in Value by Region (2020-2025)
4.2.3 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales (Volume & Value), Price and Gross Margin (2020-2025)
4.3 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Forecasted Market Size by Region
4.3.1 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales in Volume by Region (2026-2031)
4.3.2 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales in Value by Region (2026-2031)
4.3.3 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Sales (Volume & Value), Price and Gross Margin (2026-2031)
5 Proliferative Vitreoretinopathy (PVR) Therapeutics by Application
5.1 Proliferative Vitreoretinopathy (PVR) Therapeutics Market by Application
5.1.1 Clinic
5.1.2 Hospital
5.1.3 ASCs
5.1.4 Others
5.2 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Market Size by Application
5.2.1 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Market Size Overview by Application (2020-2031)
5.2.2 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Historic Market Size Review by Application (2020-2025)
5.2.3 Global Proliferative Vitreoretinopathy (PVR) Therapeutics Forecasted Market Size by Application (2026-2031)
5.3 Key Regions Market Size by Application
5.3.1 North America Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Breakdown by Application (2020-2025)
5.3.2 Europe Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Breakdown by Application (2020-2025)
5.3.3 Asia-Pacific Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Breakdown by Application (2020-2025)
5.3.4 South America Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Breakdown by Application (2020-2025)
5.3.5 Middle East and Africa Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Breakdown by Application (2020-2025)
6 Company Profiles
6.1 Novartis AG
6.1.1 Novartis AG Comapny Information
6.1.2 Novartis AG Business Overview
6.1.3 Novartis AG Proliferative Vitreoretinopathy (PVR) Therapeutics Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Novartis AG Proliferative Vitreoretinopathy (PVR) Therapeutics Product Portfolio
6.1.5 Novartis AG Recent Developments
6.2 RXi Pharmaceuticals Corp
6.2.1 RXi Pharmaceuticals Corp Comapny Information
6.2.2 RXi Pharmaceuticals Corp Business Overview
6.2.3 RXi Pharmaceuticals Corp Proliferative Vitreoretinopathy (PVR) Therapeutics Sales, Revenue and Gross Margin (2020-2025)
6.2.4 RXi Pharmaceuticals Corp Proliferative Vitreoretinopathy (PVR) Therapeutics Product Portfolio
6.2.5 RXi Pharmaceuticals Corp Recent Developments
6.3 Promedior Inc
6.3.1 Promedior Inc Comapny Information
6.3.2 Promedior Inc Business Overview
6.3.3 Promedior Inc Proliferative Vitreoretinopathy (PVR) Therapeutics Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Promedior Inc Proliferative Vitreoretinopathy (PVR) Therapeutics Product Portfolio
6.3.5 Promedior Inc Recent Developments
7 North America by Country
7.1 North America Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Country
7.1.1 North America Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
7.1.2 North America Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Country (2020-2025)
7.1.3 North America Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Forecast by Country (2026-2031)
7.2 North America Proliferative Vitreoretinopathy (PVR) Therapeutics Market Size by Country
7.2.1 North America Proliferative Vitreoretinopathy (PVR) Therapeutics Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
7.2.2 North America Proliferative Vitreoretinopathy (PVR) Therapeutics Market Size by Country (2020-2025)
7.2.3 North America Proliferative Vitreoretinopathy (PVR) Therapeutics Market Size Forecast by Country (2026-2031)
8 Europe by Country
8.1 Europe Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Country
8.1.1 Europe Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
8.1.2 Europe Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Country (2020-2025)
8.1.3 Europe Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Forecast by Country (2026-2031)
8.2 Europe Proliferative Vitreoretinopathy (PVR) Therapeutics Market Size by Country
8.2.1 Europe Proliferative Vitreoretinopathy (PVR) Therapeutics Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
8.2.2 Europe Proliferative Vitreoretinopathy (PVR) Therapeutics Market Size by Country (2020-2025)
8.2.3 Europe Proliferative Vitreoretinopathy (PVR) Therapeutics Market Size Forecast by Country (2026-2031)
9 Asia-Pacific by Country
9.1 Asia-Pacific Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Country
9.1.1 Asia-Pacific Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
9.1.2 Asia-Pacific Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Country (2020-2025)
9.1.3 Asia-Pacific Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Forecast by Country (2026-2031)
9.2 Asia-Pacific Proliferative Vitreoretinopathy (PVR) Therapeutics Market Size by Country
9.2.1 Asia-Pacific Proliferative Vitreoretinopathy (PVR) Therapeutics Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
9.2.2 Asia-Pacific Proliferative Vitreoretinopathy (PVR) Therapeutics Market Size by Country (2020-2025)
9.2.3 Asia-Pacific Proliferative Vitreoretinopathy (PVR) Therapeutics Market Size Forecast by Country (2026-2031)
10 South America by Country
10.1 South America Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Country
10.1.1 South America Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
10.1.2 South America Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Country (2020-2025)
10.1.3 South America Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Forecast by Country (2026-2031)
10.2 South America Proliferative Vitreoretinopathy (PVR) Therapeutics Market Size by Country
10.2.1 South America Proliferative Vitreoretinopathy (PVR) Therapeutics Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
10.2.2 South America Proliferative Vitreoretinopathy (PVR) Therapeutics Market Size by Country (2020-2025)
10.2.3 South America Proliferative Vitreoretinopathy (PVR) Therapeutics Market Size Forecast by Country (2026-2031)
11 Middle East and Africa by Country
11.1 Middle East and Africa Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Country
11.1.1 Middle East and Africa Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
11.1.2 Middle East and Africa Proliferative Vitreoretinopathy (PVR) Therapeutics Sales by Country (2020-2025)
11.1.3 Middle East and Africa Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Forecast by Country (2026-2031)
11.2 Middle East and Africa Proliferative Vitreoretinopathy (PVR) Therapeutics Market Size by Country
11.2.1 Middle East and Africa Proliferative Vitreoretinopathy (PVR) Therapeutics Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
11.2.2 Middle East and Africa Proliferative Vitreoretinopathy (PVR) Therapeutics Market Size by Country (2020-2025)
11.2.3 Middle East and Africa Proliferative Vitreoretinopathy (PVR) Therapeutics Market Size Forecast by Country (2026-2031)
12 Value Chain and Sales Channels Analysis
12.1 Proliferative Vitreoretinopathy (PVR) Therapeutics Value Chain Analysis
12.1.1 Proliferative Vitreoretinopathy (PVR) Therapeutics Key Raw Materials
12.1.2 Key Raw Materials Price
12.1.3 Raw Materials Key Suppliers
12.1.4 Manufacturing Cost Structure
12.1.5 Proliferative Vitreoretinopathy (PVR) Therapeutics Production Mode & Process
12.2 Proliferative Vitreoretinopathy (PVR) Therapeutics Sales Channels Analysis
12.2.1 Direct Comparison with Distribution Share
12.2.2 Proliferative Vitreoretinopathy (PVR) Therapeutics Distributors
12.2.3 Proliferative Vitreoretinopathy (PVR) Therapeutics Customers
13 Concluding Insights
14 Appendix
14.1 Reasons for Doing This Study
14.2 Research Methodology
14.3 Research Process
14.4 Authors List of This Report
14.5 Data Source
14.5.1 Secondary Sources
14.5.2 Primary Sources
14.6 Disclaimer
How Do Licenses Work?
Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.